Literature DB >> 33373063

Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.

Jennifer R Brown1,2, Sarah R Walker1,2, Lisa N Heppler1, Svitlana Tyekucheva3, Erik A Nelson1,2, Josephine Klitgaard1, Maria Nicolais1, Yasmin Kroll1, Michael Xiang1, Jennifer E Yeh1, Mousumi Chaudhury1, Zachary T Giaccone1, Stacey M Fernandes1, Eric D Jacobsen1,2, David C Fisher1,2, Arnold S Freedman1,2, Matthew S Davids1,2, Jeffrey G Supko4, Catherine Wu1,2, David A Frank1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33373063      PMCID： PMC7954938          DOI： 10.1002/ajh.26084

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.

Authors:  Ayumi Takakura; Erik A Nelson; Nadeem Haque; Benjamin D Humphreys; Kambiz Zandi-Nejad; David A Frank; Jing Zhou
Journal:  Hum Mol Genet       Date:  2011-08-05       Impact factor: 6.150

2.  STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.

Authors:  Inbal Hazan-Halevy; David Harris; Zhiming Liu; Jie Liu; Ping Li; Xiaomin Chen; Sreejesh Shanker; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

3.  B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.

Authors:  D A Frank; S Mahajan; J Ritz
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 4.  STAT3 as a central mediator of neoplastic cellular transformation.

Authors:  David A Frank
Journal:  Cancer Lett       Date:  2006-11-28       Impact factor: 8.679

5.  Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

Authors:  Lili Wang; Alex K Shalek; Mike Lawrence; Ruihua Ding; Jellert T Gaublomme; Nathalie Pochet; Petar Stojanov; Carrie Sougnez; Sachet A Shukla; Kristen E Stevenson; Wandi Zhang; Jessica Wong; Quinlan L Sievers; Bryan T MacDonald; Alexander R Vartanov; Natalie R Goldstein; Donna Neuberg; Xi He; Eric Lander; Nir Hacohen; Aviv Regev; Gad Getz; Jennifer R Brown; Hongkun Park; Catherine J Wu
Journal:  Blood       Date:  2014-04-28       Impact factor: 22.113

Review 6.  A chemical biology approach to developing STAT inhibitors: molecular strategies for accelerating clinical translation.

Authors:  Erik A Nelson; Sreenath V Sharma; Jeffrey Settleman; David A Frank
Journal:  Oncotarget       Date:  2011-06
  6 in total
  4 in total

1.  MDACT: A New Principle of Adjunctive Cancer Treatment Using Combinations of Multiple Repurposed Drugs, with an Example Regimen.

Authors:  Richard E Kast; Alex Alfieri; Hazem I Assi; Terry C Burns; Ashraf M Elyamany; Maria Gonzalez-Cao; Georg Karpel-Massler; Christine Marosi; Michael E Salacz; Iacopo Sardi; Pieter Van Vlierberghe; Mohamed S Zaghloul; Marc-Eric Halatsch
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

2.  Pyrimethamine inhibits cell growth by inducing cell senescence and boosting CD8+ T-cell mediated cytotoxicity in colorectal cancer.

Authors:  Haiyan Dong; Limei Hu; Weiqian Li; Mengchen Shi; Lingyuan He; Chen Wang; Yijia Hu; Huihui Wang; Chuangyu Wen; Huanliang Liu; Xiangling Yang
Journal:  Mol Biol Rep       Date:  2022-03-09       Impact factor: 2.742

Review 3.  STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma.

Authors:  Mingjing Jiang; Bo Li
Journal:  Cells       Date:  2022-10-05       Impact factor: 7.666

Review 4.  Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.

Authors:  Haoyang Huang; Qing He; Binghua Guo; Xudong Xu; Yinjuan Wu; Xuerong Li
Journal:  Drug Des Devel Ther       Date:  2021-06-22       Impact factor: 4.162
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.